AstraZeneca CEO Soriot bets up to $7B on a major league collaboration for a game-changing HER2 cancer drug

After years of out-licensing, product sales and whatever else it took to float the sinking AstraZeneca ship, CEO Pascal Soriot is now a buyer. And he's going big.

Thursday night, Soriot announced that AstraZeneca is paying Daiichi Sankyo $1.35 billion upfront to partner on trastuzumab deruxtecan, an antibody drug conjugate for HER2 expressing cancers. Half arrives with the signing, the other half in a year. And Soriot is adding up to $5.55 billion more in development and commercial milestones, for a total of $6.9 billion, one of the largest pacts the company has ever struck.

Pascal Soriot in Washington, DC, February 2019 Getty

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->